HOT Screen GmbH from Reutlingen, Germany, develops human organotypical (HOT) cell culture models related to the human immune system for the assessment of drug activity profiles and the selection of suitable drug candidates. For the past 17 years or so, Dr. Manfred Schmolz, managing director of HOT Screen GmbH, and his scientific team have devoted their creativity and energy to the development of such physiological models. The sophisticated models are made with differentiated cells and can be adapted to a broad range of different diseases - including rheumatoid arthritis, osteoarthritis, Crohn’s disease, neurodermatitis, COPD, asthma and many others. Pharmaceutical companies and the biotechnology industry contact HOT Screen GmbH with specific issues and Dr. Schmolz not only listens carefully to their requirements, but in many cases has a suitable model already available.
Around 90 percent of all drug candidates fail to complete the clinical development and marketing approval process. The decision to abandon the drug candidate usually occurs relatively late in the drug discovery process after many years of preclinical and clinical research. Dr. Schmolz is convinced that it is possible to improve the effectiveness of the processes. It is also possible to decide at an earlier stage whether it is worthwhile investing in the further development of a substance class under investigation. However, this decision depends on the availability of differentiated, organotypical models that can be used for the preclinical evaluation of drug candidates.
Since it is not possible to implement all the functions of an organ such as the kidneys, the HOT Screen GmbH models can represent neither a complete nor a real in-vivo situation. That said, this is not HOT Screen GmbH’s primary objective. Schmolz knows from his own experience that a physiological section is perfectly sufficient for finding answers to relevant questions. Of course, Schmolz has specific ideas as to how certain models could be optimised in physiological terms.
Due to their interaction with the immune system, Schmolz believes that the inclusion of neuroendocrine system cells or the liver in the model would be advantageous in the evaluation of drug activity profiles. However, even though the model can be developed further, this is not what the pharmaceutical industry is primarily seeking. Any characterisation of active drug ingredients must lead to highly reproducible results, but it goes without saying that this becomes increasingly difficult with the increasing complexity of a drug. Testing drugs in animals is not a satisfactory solution either, as the results cannot be transferred 100% to the situation in humans.
EDI GmbH was renamed on the 1th July 2014 as HOT Screen GmbH.
Further information:Dr. Manfred SchmolzHOT Screen GmbH Aspenhaustr. 25 72770 Reutlingen Tel.: +49 (0)7121/434103E-mail: m.schmolz(at)hot-screen.de